EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Update on the current and future use of CAR‐T to treat multiple myeloma

Zhubin Gahvari, Matthew Brunner, Timothy Schmidt iD, Natalie S Callander iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Zhubin Gahvari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-…. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T‐cell (CAR‐T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B‐cell maturation antigen (BCMA) is the most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing expression of this essential transmembrane protein on malignant plasma cells as patients develop more advanced disease. This review will explore the earliest CAR‐T trials in myeloma, discuss important issues involved in CAR‐T manufacturing and processing, as well as review current clinical trials that led to the approval of the two commercially available CAR‐T products, Idecabtagene vicleucel and ciltacabtagene autoleucel. The most recent data from trials investigating the use of CAR‐T as an earlier line of therapy will be presented. Finally, the problem of relapses after CAR‐T will be presented, including several theories as to why CAR‐T therapies fail and possible clinical caveats. The next generation of MM‐specific CAR‐T will likely include new targets such as G‐protein‐coupled receptor class C, Group 5, member D (GPRC5D) and signaling lymphocyte activation molecular Family 7 (SLAMF7). The role of CAR‐T in the treatment of MM will undoubtedly increase exponentially in the next decade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaReceptors, Chimeric AntigenHumansPlasma CellsB-Cell Maturation AntigenImmunotherapy, AdoptiveMembrane Proteins

Stichwörter der Autor:innen

BCMAchimeric antigen receptor T-cellmultiple myeloma

Substanzen

Receptors, Chimeric AntigenB-Cell Maturation AntigenMembrane Proteins

Autor:innen und Institutionen

  • Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

ORCID-Profile: Timothy Schmidt, Natalie S Callander

Förderung

  • NCI NIH HHS

Zitieren

APA

Gahvari, Z., Brunner, M., Schmidt, T., & Callander, N. S. (2024). Update on the current and future use of CAR‐T to treat multiple myeloma. European Journal of Haematology. https://doi.org/10.1111/ejh.14145

Vancouver

Gahvari Z, Brunner M, Schmidt T, Callander NS. Update on the current and future use of CAR‐T to treat multiple myeloma. European Journal of Haematology. 2024. doi:10.1111/ejh.14145

BibTeX
@article{Gahvari2024,
  author = {Gahvari, Zhubin and Brunner, Matthew and Schmidt, Timothy and Callander, Natalie S},
  title = {Update on the current and future use of CAR‐T to treat multiple myeloma},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14145}
}
Kostenlos starten →